New Medicine Group Challenges and Achievements Saad Al-Ismail







Overview

Introduction

- Structure of appraisal
- •Similarity and differences from AWMSG

Challenges





•AWMSG - 2002

•NMG Inaugural Meeting- May 2007

- NMG Constitution update October 2013
- Membership reviewed November 2013
 - Appointed by AWMSG Steering Committee
 - •AWMSG member may not serve on NMG
 - AWMSG deputy member may

New Medicine Group Voting members Chair •1 Lay Member •3 Pharmacists (from primary an Cook •3 Doctors (from primary a lecond •1 Profession allied t or representative or other coressio Sallowed to prescribe •1 Nurse •1 PHW representati •1 Health Econ mist **Deputies**

•1 ABPI Cymru Walk Pepresentative

•1 Welsh Health Specialised Services Committee representative



Non-voting attendees

- •AWTTC
- Health Economist
- AWMSG
- Chair or nominee
- Welsh Government
 - •Chief Pharmaceutical Officer or representative AWMSG
- Medicine and Therapeutic Committees

Structure of Appraisal – Evidence

- Evidence submitted by company
 - •Form B or Form C
- •AWTTC -ASAR
- Clinical Expert(s)
- Patient Organisation(s)
- Consider innovative nature of medicine
- Particular features of condition and target population

al Effectiveness



- •Lead Assessor Voting member
- Clinical Expert
- Patient's view
- •ABPI representative

NMG does not consider

- Budget Impact
- Societal Issues





Proceedings -

- Declaration of interest
- Chairman report

Full Appraisal

Clinical Effectiveness

- •NMG Lead Assessor to provide overview
- •AWTTC Appraisal Lead to highlight any issues
- Consider the case of clinical effectiveness
 - Clinical Expert(s) views

Clinical Expert



Clinical experts are invited to attend NMG to observe proceedings and answer questions in order to provide NMG with a better understanding of the clinical context. Clinical experts are usually nominated by their specialist groups and, therefore, should not express personal opinion or promote a medicine. Clinical experts will declare any personal or nonspecific interests at the outset of the appraisal and will leave the meeting prior to the vote.

New Medicine Group Proceedings -



- Declaration of interest
- Chairman reportFull Appraisal
- Clinical Effectiveness
- •Consider the case for cos offectiveness
 - •AWTTC health examist to highlight salient issues
- •Lay member to present patient / lay perspective
- •ABPI Wales representative to comment
- General discussion



Limited submissions

No requirement for a presentation by a NMG Lead Assessor AWTTC appraisal Lead presents recommendation to NMG Discuss any outstanding issues

NMG members to vote on the draft PAR

(If not approved, a fuller appraisal and discussion to proceed followed by another vote).

New Medicine Group Challenges and Opportunities



Clinical effectiveness

- Outcomes from pivotal trials
 - Unmet needs
 - Comparator(s)
- Engagement of clinical expert(s)
- Support by patients/ organisation

New Medicine Group Challenges and Opportunities



Cost effectiveness

- Health economic model
 - •CUA
 - •CMA
- Data derived from pivotal trials
- Relevant Comparators
- Appropriate ICER







New Medicine Group Outcome - PAR



- •Full appraisals
- Limited appraisals
 - Approved
 - Not approved
- Outcome from AWMSG
 - Support NMG PAR
 - Did not support NMG PAR



Thank You





www.awttc.or

All Wales Therapeutics and Toxicology Centre Academic Building University Hospital Llandough Penlan Road Penarth Vale of Glamorgan CF64 2XX













Comparison of Appraisal Recommendations (Full Submissions)



	NMG	AWMSG
	PAR NMG to AWMSG Oct 15 to Sept 16	FAR AWMSG to WG Nov 15 to Oct 16
Recommended	37	42
Not recommended	8	3
Total	45	45

